Investment Analysts’ Recent Ratings Updates for Tempus AI (TEM)

A number of research firms have changed their ratings and price targets for Tempus AI (NASDAQ: TEM):

• 10/12/2026 – Tempus AI had its price target raised by Canaccord Genuity Group Inc. from $80.00 to $95.00. They now have a “buy” rating on the stock.
• 10/1/2026 – Tempus AI had its price target raised by Guggenheim from $65.00 to $92.00. They now have a “buy” rating on the stock.
• 9/28/2026 – Tempus AI was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 9/21/2026 – Tempus AI is now covered by The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $75.00 price target on the stock.
• 9/21/2026 – Tempus AI is now covered by The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $75.00 price target on the stock.
• 9/11/2026 – Tempus AI was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 9/11/2026 – Tempus AI had its price target raised by HC Wainwright from $56.00 to $66.00. They now have a “buy” rating on the stock.
• 9/9/2026 – Tempus AI is now covered by UBS Group AG. They set a “neutral” rating and a $70.00 price target on the stock.
• 9/8/2026 – Tempus AI is now covered by Rothschild & Co Redburn. They set a “neutral” rating and a $67.00 price target on the stock.
• 9/8/2026 – Tempus AI is now covered by Rothschild & Co Redburn. They set a “neutral” rating and a $67.00 price target on the stock.
• 9/8/2026 – Tempus AI is now covered by Roth Capital. They set a “neutral” rating and a $67.00 price target on the stock.
• 9/2/2026 – Tempus AI was given a new $80.00 price target by Raymond James Financial, Inc..
• 9/2/2026 – Tempus AI is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $80.00 price target on the stock.
• 9/1/2026 – Tempus AI was upgraded by Piper Sandler from “neutral” to “overweight”. They now have a $76.00 price target on the stock, up from $56.00.
• 8/27/2026 – Tempus AI was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 8/20/2026 – Tempus AI had its price target raised by BTIG Research from $70.00 to $80.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In other Tempus AI news, CEO Ryan Fukushima sold 41,095 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $2,038,722.95. Following the sale, the chief executive officer owned 562,463 shares of the company’s stock, valued at approximately $27,903,789.43. This trade represents a 6.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James Rogers sold 26,313 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $60.00, for a total transaction of $1,578,780.00. Following the sale, the chief financial officer directly owned 106,024 shares in the company, valued at approximately $6,361,440. The trade was a 19.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 1,280,965 shares of company stock valued at $80,397,564. 24.26% of the stock is owned by company insiders.

Tempus AI, Inc is a technology company focused on applying artificial intelligence and data analytics to precision medicine. The company develops tools intended to help physicians make more informed treatment decisions by combining clinical information, molecular data and other health-related datasets.

Tempus provides genomic testing and diagnostic services, including sequencing and other molecular tests used primarily in oncology. Its platform also offers data and software solutions designed to support clinical research, pharmaceutical development, patient identification for clinical trials and the development of personalized treatment strategies.

Founded in 2015, Tempus is headquartered in Chicago and primarily serves healthcare providers, researchers and life sciences companies.